Search

After immunotherapy and targeted therapy failed to bring a patient's melanoma under control, MSK doctors offered her a new treatment called tumor-infiltrating lymphocyte, or TIL, therapy.

… Tuesday, October 28, 2025 It was not the news that Pattie Fuller wanted to hear.  Doctors at a local hospital in upstate New York told her that despite surgery and several rounds of  immunotherapy , her  melanoma was growing. The melanoma ultimately grew to be stage 4. It spread from her scalp to the

Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.

… Wednesday, September 15, 2021 Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments: MSK Receives National Cancer Institute (NCI) Specialized Programs of Research Excellence (SPORE) Grant Omar Abdel-Wahab and Martin Tallman The National Cancer Institute (NCI) awarded

Despite significant advances in supportive care and improvements in allogeneic hematopoietic stem cell transplantationoutcomes, about one in every three patients succumbs to post-transplant toxicities, half of which are not related to graft-versus-host disease.

… Thursday, March 15, 2018 Despite significant advances in supportive care and improvements in allogeneic hematopoietic stem cell transplantation outcomes, about one in every three patients succumbs to post-transplant toxicities, half of which are not related to graft-versus-host disease (GVHD). While

Learn the keys to a successful telemedicine visit from a cancer specialist at Memorial Sloan Kettering.

… Wednesday, May 27, 2020 Summary A Memorial Sloan Kettering cancer expert gives tips to patients on how they can be their own best advocates and feel confident, relaxed, and in control during telemedicine video visits with their cancer doctors. People with cancer and their doctors build a strong relationship

Aprenda las claves para una visita de telemedicina exitosa de parte de una especialista en cáncer en Memorial Sloan Kettering.

… Wednesday, May 27, 2020 Resumen Una experta en cáncer de Memorial Sloan Kettering da consejos a los pacientes sobre cómo pueden ser sus mejores defensores y sentirse seguros, relajados y en control durante las visitas de telemedicina por video con sus médicos especialistas en cáncer. Las personas con

Узнайте о том, что необходимо для успешного дистанционного приема, от онколога центра Memorial Sloan Kettering.

… Wednesday, May 27, 2020 Краткое изложение Специалист по онкологии из центра Memorial Sloan Kettering дает советы пациентам по поводу того, как наилучшим образом представлять свои интересы, чувствовать себя уверенно и спокойно и сохранять контроль над ситуацией во время дистанционного видеоприема у врача-онколога

A new discovery made by Memorial Sloan Kettering researchers and published in the journal Nature Genetics, identifies a mechanism for the triggering of solid tumors — including most types of cancers that affect children and young adults. For more information or to arrange interviews, e-mail Rebecca Williams at [email protected].

… Monday, May 15, 2017 Bottom Line :  A new discovery published in the journal Nature Genetics identifies a mechanism for the triggering of solid tumors — including most types of cancers that affect children and young adults. The enzyme made by the gene PGBD5 cuts DNA segments and then rearranges them.

Cancer progression is commonly thought of as a process involving the growth of a primary tumor followed by metastasis, in which cancer cells leave the primary tumor and spread to distant organs. A new study by researchers at Memorial Sloan Kettering Cancer Center shows that circulating tumor cells - cancer cells that break away from a primary tumor and disseminate to other areas of the body - can also return to and grow in their tumor of origin, a newly discovered process called "self-seeding."

… Thursday, December 24, 2009 Cancer progression is commonly thought of as a process involving the growth of a primary tumor followed by metastasis, in which cancer cells leave the primary tumor and spread to distant organs. A new study by researchers at Memorial Sloan Kettering Cancer Center shows that

… Friday, November 8, 2024 Memorial Sloan Kettering Cancer Center (MSK) issued the following statement regarding its financial results for the first three quarters of 2024:   MSK’s financial performance through the third quarter of 2024 demonstrate positive and consistent financial results, with an excess

New data from researchers at MSK featured in the 2022 ASCO Annual Meeting press program and simultaneously published in The New England Journal of Medicine highlights a novel antibody-drug conjugate that doubled progression-free survival in HER2-low metastatic breast cancer.

… Sunday, June 5, 2022 Update: On August 5, 2022, the FDA approved the first targeted therapy for patients with HER2-low  breast cancer  that has spread to other parts of the body and is unable to be surgically removed. The drug,  https://www.mskcc.org/cancer-care/patient-education/fam-trastuzumab-deruxtecan